Corbus Pharmaceuticals Holdings, Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
DE
Business Address
500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
Mailing Address
500 RIVER RIDGE DRIVE, NORWOOD, MA, 02062
Phone
617-963-0103
Fiscal Year End
1231
EIN
464348039
Financial Overview
FY2025
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| DEF 14A Definitive proxy statement | April 2, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 11, 2026 | View on SEC |
| 10-K Annual financial report | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 4 Insider stock transaction report | March 4, 2026 | View on SEC |
| 8-K Current report of material events | February 25, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| 4 Insider stock transaction report | February 18, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
Annual Reports
10-K
March 9, 2026
- Advancing two promising drug candidates: CRB-701 (oncology, Phase 1/2) and CRB-913 (obesity, Phase 1).
- Strategic shift to oncology solidified by the acquisition of CRB-701 rights in February 2023.
Insider Trading
STRONG SELL
5 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.